Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is using its experience and expertise in manufacturing and production to rapidly develop COR1 for internal development and downstream commercialization. With key catalysts ahead, including the ongoing Phase 2a GAlette study and potential updates from Roche and Genentech, as well as advancements in its AlloSCOPE platform for scalability and stability, Lineage's innovative approach could lead to a competitive advantage in the emerging cell therapy market. Their focus on employing advanced biologic diagnostics and differentiation techniques to control purity and quality of their stem cell-based product is another positive sign for investors.

Bears say

Lineage Cell Therapeutics is experiencing positive results with its retinal pigment epithelium cell therapy (OpRegen) in its Phase 1/2a study and has a partnership with Roche and Genentech. However, the company faces risk factors such as clinical and financial risks, legal and intellectual property risks, and potential competition in the market. Additionally, its pipeline includes treatments for diseases with large unmet needs but currently available therapies may not demonstrate significant visual benefits, making the commercial success of these programs uncertain.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.